Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.

West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy?

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 8:00 a.m. GMT in London, UK.

West to Participate in Upcoming Investor Conference

The average one-year price target for West Pharmaceutical Services (NYSE:WST) (BMV:WST) has been revised to $467.89 / share. This is an increase of 12.52% from the prior estimate of $415.83 dated October 20, 2026. These figures represent an aggregate of analyst targets compiled b

West Pharmaceutical Services Consensus Price Target Raised 12.52% to $467.89

West Pharmaceutical Services reported past Q3 2026 results with sales of US$874.5 million and diluted EPS from continuing operations of US$3.02, and management raised full year 2026 net sales guidance to US$3.41 billion to US$3.42 billion with expected diluted EPS of US$9.31 to US$9.41. Management linked this upgraded outlook to strong demand for high value components tied to biologics and GLP 1 therapies, while also continuing dividends, buybacks and fresh credit capacity. Together, these...

How Investors Are Reacting To West (WST) Earnings Beat

West Pharmaceutical Services (WST) just put fresh numbers on the table, reporting third quarter results and lifting its full year 2026 outlook. This gives investors new data to reassess the stock. Momentum around West Pharmaceutical Services has been building, with the share price delivering a 13.05% 1 month share price return and an 18.59% 3 month share price return ahead of these Q3 results. A 46.74% 1 year total shareholder return and 49.28% year to date share price return suggest...

West Pharmaceutical Services (WST) Lifted Its Outlook, Is The Stock Fully Priced?

Healthcare products company West Pharmaceutical Services (NYSE:WST) announced better-than-expected revenue in Q3 2026, with sales up 8.7% year on year to $874.5 million. The company’s full-year revenue guidance of $3.42 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $2.66 per share was 21.1% above analysts’ consensus estimates.

WST Q3 deep dive: Biologics and regulatory tailwinds fuel margin expansion, HVP mix shift continues

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

West Pharmaceutical Services, Inc. News